Vancomycin-resistant Staphylococcus aureus historical perspective

Vancomycin-resistant Staphylococcus aureus Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Vancomycin-resistant Staphylococcus aureus historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Vancomycin-resistant Staphylococcus aureus historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Vancomycin-resistant Staphylococcus aureus historical perspective
CDC on Vancomycin-resistant Staphylococcus aureus historical perspective
Vancomycin-resistant Staphylococcus aureus historical perspective in the news
Blogs on Vancomycin-resistant Staphylococcus aureus historical perspective
Directions to Hospitals Treating Vancomycin-resistant Staphylococcus aureus
Risk calculators and risk factors for Vancomycin-resistant Staphylococcus aureus historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

VISA (vancomycin-intermediate Staphylococcus aureus) was first identified in Japan in 1996 and has since been found in hospitals in England, France, the U.S., Asia and Brazil. It is also termed GISA (glycopeptide-intermediate Staphylococcus aureus) indicating resistance to all glycopeptide antibiotics. These bacterial strains present a thickening of the cell wall which is believed to deplete the vancomycin available to kill the bacteria.